These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7298290)

  • 1. Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
    Drago JR; Worgul TJ
    Invest Urol; 1981 Nov; 19(3):191-3. PubMed ID: 7298290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic treatment of the Nb rat adenocarcinoma androgen-insensitive tumor III.
    Drago JR
    J Surg Oncol; 1982 Dec; 21(4):264-6. PubMed ID: 7144207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of the Nb rat in combination chemotherapeutic experiments for prostate cancer.
    Drago JR; Smith J
    In Vivo; 1991; 5(1):41-2. PubMed ID: 1932624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chemotherapeutic responsiveness in Nb rat prostate cancer model. 5-fluorouracil, methotrexate, cyclophosphamide, and adriamycin.
    Drago JR; Goldman L; Gershwin ME
    Invest Urol; 1980 Jul; 18(1):80-1. PubMed ID: 7410017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma.
    Drago JR; Weed P; Fralisch A
    Anticancer Res; 1984; 4(3):171-2. PubMed ID: 6540544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of an Nb-Pr-A.I.-3 (autonomous) tumor with combination chemotherapy.
    Drago JR; Worgul T
    Cancer Chemother Pharmacol; 1981; 5(3):163-6. PubMed ID: 7197592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Drago JR; Goldman LB; Maurer RE; Gershwin ME; Eckels DD
    Invest Urol; 1979 Nov; 17(3):203-6. PubMed ID: 500317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
    Drago JR; Goldman LB; Gershwin ME
    Cancer; 1980 Jul; 46(2):273-8. PubMed ID: 7388771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy in a prostate tumor model: Nb rat prostatic adenocarcinoma model.
    Drago JR; Worgul T; Gershwin ME
    J Surg Oncol; 1981; 16(4):353-63. PubMed ID: 7195962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
    Block NL; Camuzzi F; Stover B; Claflin A; Troner M; Politano VA
    Trans Am Assoc Genitourin Surg; 1978; 70():57-9. PubMed ID: 753023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Logothetis CJ; von Eschenbach AC; Samuels ML; Trindade A; Johnson DE
    Cancer Treat Rep; 1982 Jan; 66(1):57-63. PubMed ID: 7053267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nb rat prostate adenocarcinoma model: metastasis.
    Drago JR; Curley RM; Sipio JC
    Anticancer Res; 1985; 5(2):193-6. PubMed ID: 2581494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
    Denes AE; Presant CA; Bartolucci A
    Cancer Treat Rep; 1982 Jan; 66(1):199-200. PubMed ID: 7053258
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
    Bruckner HW; Deppe G
    Obstet Gynecol; 1977 Jul; 50(1 Suppl):10s-12s. PubMed ID: 876531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nb rat prostatic adenocarcinoma's dose response to methotrexate and adriamycin.
    Drago JR; Palmer J
    J Surg Oncol; 1983 Nov; 24(3):215-7. PubMed ID: 6632910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and concomitant chemoradiotherapy in the NB rat prostate adenocarcinoma model.
    Klump R; Pieters RS; Smith JJ; Badalament RA; Drago JR
    In Vivo; 1989; 3(2):109-11. PubMed ID: 2519835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of clinical therapeutic synergism between cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) in metastatic human colorectal carcinoma.
    O'Connell MJ; Moertel CG; Rubin J; Schutt AJ; Creagan ET
    Cancer Treat Rep; 1980; 64(2-3):311-3. PubMed ID: 7190870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 20. The Nb rat prostatic adenocarcinoma model system.
    Drago JR; Goldman LB; Maurer RE
    Prog Clin Biol Res; 1980; 37():265-91. PubMed ID: 7384086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.